Rethinking Menopause Hormone Therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rethinking Menopause Hormone Therapy

A JAMA Perspective outlines how updated FDA labeling may reshape menopause care.

  • By

  • Kerri Miller

  • April 23, 2026

  • 3 min

Share

  • 1

    Menopausal hormone therapy (MHT) use declined from over 20% to under 5% after the Women’s Health Initiative.

  • 2

    The FDA's removal of black box warnings on MHT presents an opportunity for improved patient care.

  • 3

    Research shows that initiating MHT before age 60 or within 10 years of menopause has a favorable benefit-risk profile.

  • 4

    There are significant gaps in menopause education and symptom screening among clinicians treating middle-aged women.

  • 5

    The FDA label change emphasizes the need for routine symptom assessment and individualized discussions about MHT.

Original Source(s)

Rethinking Menopause Hormone Therapy

  • by Kerri Miller

  • April 23, 2026

Related Content

Physicians Exiting Practice Earlier

Researchers identify burnout-associated workplace pressures and caregiving responsibilities as major contributors to physician attrition.

Medical Oddities: Could GLP-1s Curb Violence?

Five studies, one question: are we overlooking hidden drivers of health?

Estriol may ease menopause-related cognitive decline

Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.